Srinivas Akkaraju is Director at SEATTLE GENETICS INC /WA (SGEN). They have made 72 open-market trades across 17 companies since 2005, most recently 2026-09-08.
CIK 0001253170
47 open-market purchases totalling $319.3M since 2009, against 25 sales. Across 46 scored buys the stock is up 31.7% at ninety days, and 29.8 points ahead of the S&P over the same stretch.
47 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 45% | 40% | 46% |
| Avg Move | +0.9% | +2.6% | +31.7% |
| Alpha | +1.2% | +2.1% | +29.8% |
| Scored | 47 | 47 | 46 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALMS | SELL | 2026-09-08 | 2026-09-09 | $10.55 | $1.0M | -23.2% | -30.3% | — |
| ALMS | BUY | 2026-09-04 | 2026-09-09 | $10.78 | $8.3M | -23.2% | -30.3% | — |
| KLRS | BUY | 2026-05-20 | 2026-05-22 | $4.83 | $1.2M | -13.7% | -18.0% | -24.8% |
| ALMS | BUY | 2026-01-09 | 2026-01-13 | $17.00 | $10.0M | +18.9% | +21.2% | +1.8% |
| ALMS | BUY | 2025-12-05 | 2025-12-09 | $9.84 | $3.7M | -1.8% | +58.1% | +133.4% |
| ALMS | BUY | 2025-12-02 | 2025-12-04 | $7.86 | $2.6M | +34.1% | -2.2% | +239.6% |
| ALMS | BUY | 2025-11-26 | 2025-12-01 | $7.58 | $2.0M | +49.8% | +25.9% | +283.5% |
| ALMS | BUY | 2025-11-20 | 2025-11-24 | $7.20 | $1.8M | +50.9% | +54.7% | +275.2% |
| ALMS | BUY | 2025-11-17 | 2025-11-19 | $6.34 | $3.1M | +2.2% | +55.7% | +266.6% |
| ALMS | BUY | 2025-11-13 | 2025-11-17 | $5.25 | $2.9M | +28.9% | +77.8% | +346.7% |
| SRRK | BUY | 2025-10-07 | 2025-12-16 | $39.85 | $1.9M | -0.3% | +2.7% | -11.2% |
| SRRK | BUY | 2025-10-03 | 2025-10-07 | $37.66 | $25.7M | -31.7% | -29.6% | +4.5% |
| MLYS | BUY | 2025-09-04 | 2025-09-08 | $25.50 | $30.0M | +8.7% | +2.2% | +4.1% |
| ALMS | BUY | 2025-05-02 | 2025-05-06 | $4.63 | $2.2M | +20.1% | -28.4% | -12.6% |
| MLYS | BUY | 2025-03-13 | 2025-03-17 | $13.50 | $8.1M | +3.7% | -6.6% | -7.0% |
| NGNE | BUY | 2024-11-26 | 2024-11-27 | $25.79 | $2.5M | -11.3% | -14.0% | -37.3% |
| SRRK | SELL · 10b5-1 | 2024-10-07 | 2024-10-07 | $29.63 | $39.4M | -11.6% | -10.5% | +29.5% |
| ALMS | BUY | 2024-07-01 | 2024-08-27 | $16.00 | $25.0M | -7.4% | -6.0% | -26.1% |
| SYRS | BUY | 2023-12-21 | 2023-12-26 | $4.42 | $8.0M | -4.8% | -8.8% | -11.7% |
| CRGX | BUY | 2023-11-14 | 2023-11-16 | $15.00 | $10.0M | +5.1% | +22.6% | +47.0% |
| SRRK | BUY | 2023-10-16 | 2023-10-18 | $6.85 | $30.0M | +46.4% | +54.1% | +102.2% |
| MLYS | BUY | 2023-02-14 | 2023-02-16 | $16.00 | $15.0M | +0.1% | -16.3% | -9.7% |
| KDNY | BUY | 2022-05-27 | 2022-06-01 | $14.00 | $8.0M | -1.9% | +9.3% | +28.5% |
| GRPH | BUY | 2022-04-11 | 2022-04-13 | $4.08 | $2.0M | -10.7% | -40.8% | -22.3% |
| GRPH | BUY | 2022-01-21 | 2022-01-25 | $8.90 | $1.3M | +4.3% | -0.2% | -53.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| SGEN | 41,503 | $9.5M |
| JYAC | 507,041 | $5.1M |
| KLRS | 2,224,147 | $4.5M |
| VTVT | 106,000 | $2.9M |
| SRRK | 27,971 | $1.1M |
| ICPT | 45,998 | $874K |
| KDNY | 3,300 | $133K |
| MLYS | 6,200 | $126K |
| ARAV | 576,066 | $23K |
| SYRS | 9,333 | $1K |
| BTRX | 18,801 | — |
| GEVA | 1,340,283 | — |
| Total | $371.6M |
Shares reported on the most recent Form 4, priced at the 2026-09-09 close. 2 holdings could not be priced and are excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.